Highlights

  • Optiscan Imaging (ASX:OIL) develops confocal endomicroscopy technology for real-time cellular-level imaging.
  • The company is progressing clinical programs in oncology and robotic-assisted surgery applications.
  • Optiscan launched its InSpecta veterinary imaging platform in the US market during 2026.
  • The company reported cash resources supporting continued clinical and commercial development activities.

Optiscan Imaging has continued advancing its medical imaging technology platform through clinical studies, commercial initiatives and strategic collaborations. The company is focused on developing confocal endomicroscopy solutions that enable real-time tissue imaging for surgical, pathology and veterinary applications.

The company remains in a development and commercialisation phase, with future growth dependent on regulatory progress, customer adoption and expansion of Revenue streams.

Confocal Endomicroscopy Technology Remains Core Focus

Optiscan Imaging (ASX:OIL) develops and commercialises confocal endomicroscopy technology designed to provide real-time imaging of tissue at a cellular level.

The company’s technology uses miniaturised digital microscope systems to capture three-dimensional images of tissue without requiring traditional laboratory processing.

The potential application is to provide clinicians with immediate information during procedures, supporting surgical decision-making and pathology workflows.

Clinical Programs Advance Across Healthcare Applications

A key focus for Optiscan Imaging is advancing human healthcare applications.

The company has been progressing clinical studies in breast cancer and head and neck cancer, with updates during 2026 indicating continued progress.

Optiscan has also submitted an FDA dossier for its InSpecta platform as part of its regulatory pathway.

The company’s relationship with the Mayo Clinic continues to support strategic, clinical and commercial planning, including potential applications in robotic-assisted surgery.

Veterinary Market Provides Commercial Opportunity

Optiscan Imaging (ASX:OIL) expanded its commercial strategy through the launch of InSpecta into the US veterinary market during 2026.

The veterinary segment provides a potential pathway for earlier commercial adoption compared with human medical applications, which typically involve longer regulatory processes.

The company is evaluating how its imaging technology can be applied across animal health markets while continuing development of human healthcare applications.

Mayo Clinic Collaboration Supports Development Pathway

The company maintains a multi-year Know-How Agreement with Mayo Clinic focused on integrating Optiscan’s imaging technology into surgical applications.

Robotic-assisted breast surgery has been identified as an initial target application.

The collaboration provides access to clinical expertise while supporting evaluation of potential healthcare applications.

Future updates regarding the Partnership will remain an important Factor for assessing commercial progress.

Financial Position Supports Development Activities

Optiscan Imaging remains a pre-profit medical technology company investing in clinical and commercial development.

The company reported approximately $18 million in cash as of December 2025.

Trailing twelve-month cash burn was estimated at approximately $6.8 million, reflecting Investment into clinical programs, product development and commercial initiatives.

Revenue remains limited, with total revenue reported at approximately $2.4 million and Operating Revenue of around $697,000.

The company also received a $1.69 million R&D tax incentive refund during 2026.

Healthcare Technology Market Exposure

Optiscan Imaging (ASX:OIL) operates within the broader medical technology sector, targeting opportunities across oncology, digital pathology and veterinary diagnostics.

The company’s technology aims to address challenges associated with traditional tissue analysis methods by providing real-time imaging capabilities.

However, commercial success depends on regulatory approvals, healthcare adoption and establishing Recurring Revenue streams.

Key Factors Investors May Monitor

Future developments for Optiscan Imaging will focus on clinical study progress, regulatory updates and commercial adoption of its imaging platforms.

Investors will monitor outcomes from the Mayo Clinic collaboration, progress of the InSpecta regulatory pathway and updates from oncology studies.

Quarterly Cash Flow reports will also provide insight into development spending and funding requirements.

Risks and Challenges

Optiscan Imaging faces risks associated with medical device development, regulatory approval timelines and commercial adoption. The company remains pre-profit, with current revenue below the level required to support operations independently.

Further Capital may be required if development expenditure continues to exceed revenue generation. Clinical progress does not guarantee regulatory approval or widespread market adoption, while healthcare technology markets can involve lengthy sales cycles and competitive pressures.

Looking Ahead

Optiscan Imaging is progressing multiple opportunities across human healthcare and veterinary applications while continuing to develop its confocal imaging technology.

The company’s next stage will depend on translating clinical progress into regulatory approvals, commercial agreements and sustainable revenue growth.

For Optiscan Imaging (ASX:OIL), the ability to convert its technology platform into broader healthcare adoption will remain the key measure of progress.

Conclusion

Optiscan Imaging has continued building its medical imaging platform through clinical studies, strategic collaborations and expansion into veterinary applications.

The company’s confocal endomicroscopy technology provides exposure to potential growth areas in surgical imaging and digital pathology.

However, Optiscan remains a development-stage MedTech company where regulatory outcomes, commercial adoption and financial management will determine future performance.